A Georgia bank that expanded to roughly $4 billion in assets through a spring merger just reported its best quarter since the deal closed, but the way it got there matters more than the headline ...
GeneDx said Tuesday it plans to add long-read whole genome sequencing to its genome testing portfolio to close diagnostic gaps and deliver diagnosis faster. The company said long-read ...
GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced plans to enhance its genome testing portfolio with long-read whole ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results